Avenue Therapeutics, Inc. (ATXI)
Market Cap | 3.21M |
Revenue (ttm) | n/a |
Net Income (ttm) | -7.18M |
Shares Out | 940.99K |
EPS (ttm) | -7.90 |
PE Ratio | n/a |
Forward PE | 17.99 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 15,538 |
Open | 3.526 |
Previous Close | 3.500 |
Day's Range | 3.340 - 3.526 |
52-Week Range | 3.250 - 93.750 |
Beta | -0.11 |
Analysts | Strong Buy |
Price Target | 56.25 (+1,549.56%) |
Earnings Date | Aug 8, 2024 |
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ATXI stock is "Strong Buy" and the 12-month stock price forecast is $56.25.
News
![](https://cdn.snapi.dev/images/v1/v/y/conf5-2487892.jpg)
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/3/s/press12-2434636.jpg)
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024
![](https://cdn.snapi.dev/images/v1/8/1/press20-2431978.jpg)
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or...
![](https://cdn.snapi.dev/images/v1/6/p/press2-2396806.jpg)
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
![](https://cdn.snapi.dev/images/v1/m/j/press12-2387707.jpg)
Avenue Therapeutics Announces Reverse Stock Split
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
![](https://cdn.snapi.dev/images/v1/i/r/press8-2339664.jpg)
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
![](https://cdn.snapi.dev/images/v1/z/7/press16-2329647.jpg)
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 -
![](https://cdn.snapi.dev/images/v1/u/n/press4-2326369.jpg)
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
![](https://cdn.snapi.dev/images/v1/w/b/conf4-2317588.jpg)
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of r...
![](https://cdn.snapi.dev/images/v1/z/b/press11-2288434.jpg)
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
-In vivo data supports BAER-101's unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy- -In vivo dat...
![](https://cdn.snapi.dev/images/v1/t/h/conf13-2225521.jpg)
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/2/m/press13-2218192.jpg)
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/f/y/press18-2216349.jpg)
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/t/d/press5-2213156.jpg)
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical c...
![](https://cdn.snapi.dev/images/v1/f/b/conf11-2179652.jpg)
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/t/b/press12-2155484.jpg)
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society (A...
![](https://cdn.snapi.dev/images/v1/d/a/press14-2137358.jpg)
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/0/q/press2-2130435.jpg)
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/u/o/conf10-2049223.jpg)
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
![](https://cdn.snapi.dev/images/v1/x/c/press1-2018433.jpg)
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in trans...
![](https://cdn.snapi.dev/images/v1/r/d/press17-1998762.jpg)
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024 -A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024
![](https://cdn.snapi.dev/images/v1/4/g/press7-1991775.jpg)
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/t/z/press15-1986193.jpg)
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
![](https://cdn.snapi.dev/images/v1/k/s/press10-1887389.jpg)
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of the...
![](https://cdn.snapi.dev/images/v1/r/p/conf20-1857693.jpg)
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
MIAMI, April 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...